Antibody therapy for Lassa fever.

Animals Antibodies, Monoclonal / therapeutic use Antibodies, Viral / therapeutic use Antigens, Viral / immunology Disease Models, Animal Epitopes Guinea Pigs Humans Immunization, Passive Lassa Fever / immunology Lassa virus Macaca

Journal

Current opinion in virology
ISSN: 1879-6265
Titre abrégé: Curr Opin Virol
Pays: Netherlands
ID NLM: 101560941

Informations de publication

Date de publication:
08 2019
Historique:
received: 23 03 2019
revised: 01 07 2019
accepted: 03 07 2019
pubmed: 12 8 2019
medline: 23 7 2020
entrez: 12 8 2019
Statut: ppublish

Résumé

Serum from convalescent Lassa fever patients was previously shown to be ineffective as a source of protective antibodies in some early studies. Subsequently, monoclonal antibodies (MAbs) to the Lassa virus (LASV) glycoprotein produced by memory B cells of West African patients who survived Lassa fever were identified. Development of MAbs as potential Lassa immunotherapeutics was facilitated by structural studies and mutational analyses that identified protective epitopes on the prefusion form of the LASV glycoprotein. Human mAbs were screened for reactivity to different neutralizing epitopes, potency, and broad reactivity against multiple lineages of LASV. MAbs were downselected in a guinea pig model of Lassa fever. A cocktail of three human MAbs designated Arevirumab-3 rescued 100% of Cynomolgus macaques at advanced stages of disease more than a week post-infection. Antibody therapeutics may be further developed in clinical trials in endemic areas potentially offering a key treatment option for Lassa fever.

Identifiants

DOI: 10.1016/j.coviro.2019.07.003 PMID: 31401518
pubmed: 31401518
pii: S1879-6257(19)30036-7
doi: 10.1016/j.coviro.2019.07.003
pii:
doi:

Substances chimiques

Antibodies, Monoclonal 0
Antibodies, Viral 0
Antigens, Viral 0
Epitopes 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

97-104

Subventions

Organisme : NIGMS NIH HHS
ID : P20 GM103501
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI104621
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI115589
Pays : United States
Organisme : NHGRI NIH HHS
ID : U01 HG007480
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI082119
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI109762
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI142790
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Robert W Cross (RW)

Department of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA; Galveston National Laboratory, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA.

Kathryn M Hastie (KM)

La Jolla Institute for Immunology, La Jolla, CA 92037, USA.

Chad E Mire (CE)

Department of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA; Galveston National Laboratory, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA.

James E Robinson (JE)

Department of Pediatrics, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA.

Thomas W Geisbert (TW)

Department of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA; Galveston National Laboratory, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA.

Luis M Branco (LM)

Zalgen Labs, LLC, Germantown, MD 20876, USA.

Erica Ollmann Saphire (E)

La Jolla Institute for Immunology, La Jolla, CA 92037, USA.

Robert F Garry (RF)

Zalgen Labs, LLC, Germantown, MD 20876, USA; Department of Microbiology and Immunology, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA. Electronic address: rfgarry@tulane.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Antibody therapy for Lassa fever.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Antibody therapy for Lassa fever.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps antiviraux › Antibody therapy for Lassa fever.
questionsmedicales.fr › Facteurs biologiques › Antigènes › Antigènes viraux › Antibody therapy for Lassa fever.
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › Antibody therapy for Lassa fever.
questionsmedicales.fr › Facteurs biologiques › Antigènes › Épitopes › Antibody therapy for Lassa fever.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Cochons d'Inde › Antibody therapy for Lassa fever.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Antibody therapy for Lassa fever.
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Immunisation passive › Antibody therapy for Lassa fever.
questionsmedicales.fr › Infection › Maladies virales › Infections à virus à ARN › Fièvres hémorragiques virales › Fièvre de Lassa › Antibody therapy for Lassa fever.
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN de polarité négative › Arenaviridae › Arenavirus › Arénavirus de l'Ancien Monde › Virus de Lassa › Antibody therapy for Lassa fever.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Cercopithecidae › Cercopithecinae › Macaca › Antibody therapy for Lassa fever.